On Nov. 18, 2025, CSL, Australia’s largest biotech company announced plans to expand its US presence with a $US 1.5 billion ($A2.3 billion) investment that will allow it to manufacture more therapies derived from blood plasma collected in the states. The funds injection could also potentially help CSL avoid or mitigate any future pharmaceutical tariffs imposed by US President Donald Trump.

“The US is the world’s leading source for plasma, the main component of plasma-derived therapies,” CSL chief executive and managing director Paul McKenzie said.

The US is one of just a handful of countries where it is legal to pay patients for their blood plasma. CSL uses it to create life-saving therapies for patients with bleeding disorders, immune deficiencies or who are suffering from trauma or burns.

The new multibillion-dollar investment will supplement CSL Behring’s existing blood plasma fractionation facility in Kankakee, Illinois, although CSL has not decided whether the new plant will be there or elsewhere. 

Melbourne-headquartered CSL said that since 2018 it had invested $3 billion in the US and added 6,500 new US jobs, bringing its total US headcount to nearly 19,000, or about two-thirds of CSL’s total workforce.